第1页 / 共14页
第2页 / 共14页
第3页 / 共14页
试读已结束，还剩11页，您可下载完整版后进行离线阅读
转移性结直肠癌全身治疗的SEOM-GEMCAD-TTD临床指南此内容为付费资源，请付费后查看
赞助会员一年免费赞助会员三年免费
付费资源
© 版权声明
1、当您下载文档后，您只拥有了使用权限，并不意味着购买了版权，文档只能用于自身学习参考，不得用于其他商业用途（如 [转卖]进行直接盈利或[编辑后售卖]进行间接盈利）。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，请自行鉴别。
3、如文档内容存在违规，或者侵犯商业秘密、侵犯著作权等，请“联系客服处理”。
4、内容来源于网络，仅限用于学习和研究目的，版权争议与本站无关。您必须在下载后的24个小时之内，从您的电脑中彻底删除上述内容。如有侵权请与我们联系处理。
THE END
Clinical and Translational Oncologyhttp5/doi.org/10.1007/s12094-023-03199-1CLINICAL GUIDES IN ONCOLOGYpkSEOM-GEMCAD-TTD clinical guidelines for the systemic treatmentof metastatic colorectal cancer(2022)Ana Fernandez Montes'.Vicente Alonso2.Enrique Aranda3.Elena Elez.Pilar Garcia Alfonso5.Cristina Gravalos5.Joan Maurel?.Ruth Vera.Rosario Vidal9.Jorge Aparicio10Received:10 April 2023/Accepted:10 April 2023©The Author(s)2O23AbstractColorectal cancer(CRC)is the second leading cause of cancer deaths in Spain.Metastatic disease is present in 15-30%ofpatients at diagnosis and up to 20-50%of those with initially localized disease eventually develop metastases.Recent scien-tific knowledge acknowledges that this is a clinically and biologically heterogeneous disease.As treatment options increase,prognosis for individuals with metastatic disease has steadily improved over recent decades.Disease management shouldbe discussed among experienced,multidisciplinary teams to select the most appropriate systemic treatment (chemotherapyand targeted agents)and to integrate surgical or ablative procedures,when indicated.Clinical presentation,tumor sidedness,molecular profile,disease extension,comorbidities,and patient preferences are key factors when designing a customizedtreatment plan.These guidelines seek to provide succinct recommendations for managing metastatic CRC.Keywords Colorectal cancer.Metastatic disease.Systemic treatment.GuidelinesAna Fernandez Montes.Vicente Alonso.Enrique Aranda.ElenaJorge AparicioElez.Pilar Garcfa Alfonso.Cristina Gravalos.Joan Maurel.Ruthjapariciou@seom.ongVera,Rosario Vidal,and Jorge Aparicio authors have contributedequally to the writing of the manuscriptMedical Oncology Department,Complexo HospitalarioUniversitario,Ourense(CHUO),C/Ramon Puga,56,☒Ana Fernandez Montes32005 Ourense,Spainafm1003@hotmail.comMedical Oncology Department,Hospital UniversitarioVicente AlonsoMiguel Servet,Saragossa.Spainvalonsoo@salud.aragon.esMedical Oncology Department,Hospital Universitario ReinaEnrique ArandaSofia,Cordoba.Spainearandaa @seom.org4Medical Oncology Department,Hospital Universitario VallElena ElezD'Hebron,Barcelona,Spainmeelez@vhio.net:mfornos @vhio.net5Medical Oncology Department,Hospital GeneralPilar Garcia AlfonsoUniversitario Gregorio Maranon,Madrid,SpainPgarcaalfonso@gmail.com6 Medical Oncology Department,Hospital Universitario 12 deCristina GravalosOctubre,Madrid,Spaincgravalos01@gmail.com7 Medical Oncology Department.Hospital Clinic,Barcelona,Joan MaurelSpainjmaurel @clinic.cats Medical Oncology Department,Hospital Universitario deRuth VeraNavarra,Pamplona,Spainruth.vera.garcia@cfnavarra.es9Medical Oncology Department,Complejo AsistencialRosario VidalUniversitario,Salamanca,Spainmrosario_vidal@hotmail.com10 Medical Oncology Department,Hospital UniversitariIPolitecnic la Fe,Valencia,SpainPublished online:03 May 2023Springer
